Literature DB >> 10352105

Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures.

T T Andreassen1, C Ejersted, H Oxlund.   

Abstract

The influence of intermittent parathyroid hormone (PTH(1-34)) administration on callus formation and mechanical strength of tibial fractures in rats was investigated after 20 and 40 days of healing. A dose of 60 microg of PTH(1-34)/kg/day and 200 microg of PTH(1-34)/kg/day, respectively, was administered during the entire periods of healing, and control animals with fractures were given vehicle. The dose of 200 microg of PTH(1-34)/kg/day increased the ultimate load and the external callus volume of the fractures by 75% and 99%, respectively, after 20 days of healing and by 175% and 72%, respectively, after 40 days of healing. The dose of 60 microg of PTH(1-34)/kg/day did not influence either ultimate load or external callus volume of the fractures after 20 days of healing, but the ultimate load was increased by 132% and the external callus volume was increased by 42% after 40 days of healing. During the healing period, the callus bone mineral content (BMC) increased in all groups. After 40 days of healing, the callus BMC was increased by 108% in the 200 microg of PTH(1-34)/kg/day group and by 76% in the 60 microg of PTH(1-34)/kg/day group. Both doses of PTH(1-34) steadily augmented the contralateral intact tibia BMC (20 days and 40 days: 60 microg of PTH (1-34)/kg/day 9% and 19%, respectively; 200 microg of PTH (1-34)/kg/day 12% and 27%, respectively) and bone mineral density (20 days and 40 days: 60 microg of PTH(1-34)/kg/day 11% and 12%, respectively; 200 microg of PTH(1-34)/kg/day 11% and 15%, respectively).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352105     DOI: 10.1359/jbmr.1999.14.6.960

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  95 in total

1.  Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis.

Authors:  Maria-Grazia Ascenzi; Vivian P Liao; Brittany M Lee; Fabrizio Billi; Hua Zhou; Robert Lindsay; Felicia Cosman; Jeri Nieves; John P Bilezikian; David W Dempster
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

2.  Delayed short-course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junction.

Authors:  Masahiko Takahata; Edward M Schwarz; Tony Chen; Regis J O'Keefe; Hani A Awad
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

3.  2011 AOA Symposium: Tissue Engineering and Tissue Regeneration: AOA critical issues.

Authors:  Scott A Rodeo; Scott D Boden; Martha M Murray; Thomas A Einhorn
Journal:  J Bone Joint Surg Am       Date:  2013-08-07       Impact factor: 5.284

Review 4.  Anabolic agents: what is beyond osteoporosis?

Authors:  Y Liu; A E Levack; E Marty; O Or; B P Samuels; M Redko; J M Lane
Journal:  Osteoporos Int       Date:  2018-04-07       Impact factor: 4.507

5.  Pulsatile release of parathyroid hormone from an implantable delivery system.

Authors:  Xiaohua Liu; Glenda J Pettway; Laurie K McCauley; Peter X Ma
Journal:  Biomaterials       Date:  2007-06-18       Impact factor: 12.479

Review 6.  Atypical femoral fractures: a review of the literature.

Authors:  Pingal A Desai; Parth A Vyas; Joseph M Lane
Journal:  Curr Osteoporos Rep       Date:  2013-09       Impact factor: 5.096

7.  The PTH-Gαs-protein kinase A cascade controls αNAC localization to regulate bone mass.

Authors:  Martin Pellicelli; Julie A Miller; Alice Arabian; Claude Gauthier; Omar Akhouayri; Joy Y Wu; Henry M Kronenberg; René St-Arnaud
Journal:  Mol Cell Biol       Date:  2014-02-18       Impact factor: 4.272

8.  Recent advances toward the clinical application of PTH (1-34) in fracture healing.

Authors:  Cara A Cipriano; Paul S Issack; Lisa Shindle; Clément M L Werner; David L Helfet; Joseph M Lane
Journal:  HSS J       Date:  2009-03-17

9.  Role of supplemental teriparatide therapy in management of osteoporotic intertrochanteric femur fractures.

Authors:  Anurag Rana; Sameer Aggarwal; Vikas Bachhal; Aman Hooda; Karan Jindal; Mandeep Singh Dhillon
Journal:  Int J Burns Trauma       Date:  2021-06-15

Review 10.  Clinical update on teriparatide.

Authors:  Elizabeth File; Chad Deal
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.